Absence of system xc− on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis

[1]  S. Gambhir,et al.  [18F]FSPG-PET reveals increased cystine/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis , 2018, Journal of Neuroinflammation.

[2]  A. Dolga,et al.  The role of Ca2+ in cell death caused by oxidative glutamate toxicity and ferroptosis. , 2017, Cell calcium.

[3]  N. Perrone-Bizzozero,et al.  Nrf2‐dysregulation correlates with reduced synthesis and low glutathione levels in experimental autoimmune encephalomyelitis , 2016, Journal of neurochemistry.

[4]  Federico N. Soria,et al.  In vivo imaging of system xc- as a novel approach to monitor multiple sclerosis , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Federico N. Soria,et al.  Cystine/glutamate antiporter blockage induces myelin degeneration , 2016, Glia.

[6]  L. Arckens,et al.  Comparative analysis of antibodies to xCT (Slc7a11): Forewarned is forearmed , 2016, The Journal of comparative neurology.

[7]  A. Massie,et al.  Main path and byways: non‐vesicular glutamate release by system xc− as an important modifier of glutamatergic neurotransmission , 2015, Journal of neurochemistry.

[8]  N. Jackman,et al.  Interleukin‐1β protects astrocytes against oxidant‐induced injury via an NF‐κB‐Dependent upregulation of glutathione synthesis , 2015, Glia.

[9]  C. Weaver,et al.  Inhibition of System Xc− Transporter Attenuates Autoimmune Inflammatory Demyelination , 2015, The Journal of Immunology.

[10]  W. Brück,et al.  Cell type-specific Nrf2 expression in multiple sclerosis lesions , 2015, Acta Neuropathologica.

[11]  T. Michiels,et al.  Lack of effect of Theiler’s murine encephalomyelitis virus infection on system x c − , 2015, Neuroscience Letters.

[12]  Zhengping Jia,et al.  Blocking GluR2–GAPDH ameliorates experimental autoimmune encephalomyelitis , 2015, Annals of clinical and translational neurology.

[13]  L. Strużyńska,et al.  Modulation of Glutamate Transport and Receptor Binding by Glutamate Receptor Antagonists in EAE Rat Brain , 2014, PloS one.

[14]  David H. Miller,et al.  Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging , 2014, The Lancet Neurology.

[15]  E. Aronica,et al.  Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. , 2014, Antioxidants & redox signaling.

[16]  Elizabeth A. McCullagh,et al.  Behavioral characterization of system xc- mutant mice , 2014, Behavioural Brain Research.

[17]  Milos Kostic,et al.  The role of glutamate and its receptors in multiple sclerosis , 2014, Journal of Neural Transmission.

[18]  Y. Ganor,et al.  The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells , 2014, Journal of Neural Transmission.

[19]  M. Prinz,et al.  Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology. , 2013, Trends in molecular medicine.

[20]  Örjan Smedby,et al.  Increased Concentrations of Glutamate and Glutamine in Normal-Appearing White Matter of Patients with Multiple Sclerosis and Normal MR Imaging Brain Scans , 2013, PloS one.

[21]  N. Perrone-Bizzozero,et al.  Increased carbonylation, protein aggregation and apoptosis in the spinal cord of mice with experimental autoimmune encephalomyelitis , 2013, ASN neuro.

[22]  P. Kalivas,et al.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. , 2013, Antioxidants & redox signaling.

[23]  Puneet Kumar,et al.  Excitotoxicity: bridge to various triggers in neurodegenerative disorders. , 2013, European journal of pharmacology.

[24]  D. Centonze,et al.  Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis , 2013, British journal of pharmacology.

[25]  R. Bridges,et al.  Thinking Outside the Cleft to Understand Synaptic Activity: Contribution of the Cystine-Glutamate Antiporter (System xc−) to Normal and Pathological Glutamatergic Signaling , 2012, Pharmacological Reviews.

[26]  R. Bridges,et al.  System xc‐ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS , 2012, British journal of pharmacology.

[27]  C. Larochelle,et al.  How do immune cells overcome the blood–brain barrier in multiple sclerosis? , 2011, FEBS letters.

[28]  C. Matute.  Glutamate and ATP signalling in white matter pathology , 2011, Journal of anatomy.

[29]  A. Castegna,et al.  Oxidative stress and reduced glutamine synthetase activity in the absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis , 2011, Neuroscience.

[30]  Federico N. Soria,et al.  Increased expression of cystine/glutamate antiporter in multiple sclerosis , 2011, Journal of Neuroinflammation.

[31]  Orla Maguire,et al.  Quantifying nuclear p65 as a parameter for NF‐κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[32]  Y. Michotte,et al.  Loss of System xc− Does Not Induce Oxidative Stress But Decreases Extracellular Glutamate in Hippocampus and Influences Spatial Working Memory and Limbic Seizure Susceptibility , 2011, The Journal of Neuroscience.

[33]  N. Plesnila,et al.  Dopaminergic neurons of system xc–‐deficient mice are highly protected against 6‐hydroxydopamine‐induced toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[35]  A. Lau,et al.  Glutamate receptors, neurotoxicity and neurodegeneration , 2010, Pflügers Archiv - European Journal of Physiology.

[36]  V. Marzo,et al.  An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis , 2010, Neurobiology of Disease.

[37]  L. Strużyńska,et al.  Alterations in glutamate transport and group I metabotropic glutamate receptors in the rat brain during acute phase of experimental autoimmune encephalomyelitis. , 2009, Folia neuropathologica.

[38]  S. Amor,et al.  Preactive lesions in multiple sclerosis , 2009, Current opinion in neurology.

[39]  P. Maher,et al.  Basal Levels of eIF2α Phosphorylation Determine Cellular Antioxidant Status by Regulating ATF4 and xCT Expression* , 2009, Journal of Biological Chemistry.

[40]  Y. Michotte,et al.  Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats , 2008, Neuroreport.

[41]  L. Strużyńska,et al.  Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis , 2008, Neuroscience.

[42]  H. Weiner,et al.  Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. , 2008, The Journal of clinical investigation.

[43]  J. Newcombe,et al.  Glutamate Receptor Expression in Multiple Sclerosis Lesions , 2008, Brain pathology.

[44]  Jun Li,et al.  System xc− Activity and Astrocytes Are Necessary for Interleukin-1β-Mediated Hypoxic Neuronal Injury , 2007, The Journal of Neuroscience.

[45]  R. Mutani,et al.  Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage , 2007, Journal of neuropathology and experimental neurology.

[46]  F. Ciruela,et al.  Glutamate Released by Dendritic Cells as a Novel Modulator of T Cell Activation1 , 2006, The Journal of Immunology.

[47]  T. Murphy,et al.  Cystine/Glutamate Exchange Modulates Glutathione Supply for Neuroprotection from Oxidative Stress and Cell Proliferation , 2006, The Journal of Neuroscience.

[48]  B. Becher,et al.  Interleukin 18–independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation , 2006, Nature Immunology.

[49]  C. Cooke,et al.  Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma , 2006, Oncogene.

[50]  R. Issels,et al.  The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death , 2006, Oncogene.

[51]  O. Boespflug-Tanguy,et al.  The large spectrum of eIF2B-related diseases. , 2006, Biochemical Society transactions.

[52]  R. Ravid,et al.  Increased expression and function of glutamate transporters in multiple sclerosis , 2006, Neurobiology of Disease.

[53]  Satoru Takahashi,et al.  Redox Imbalance in Cystine/Glutamate Transporter-deficient Mice* , 2005, Journal of Biological Chemistry.

[54]  Wei Li,et al.  Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Kaufmann,et al.  Differential requirements for the chemokine receptor CCR7 in T cell activation during Listeria monocytogenes infection , 2005, The Journal of experimental medicine.

[56]  Daniel Pelletier,et al.  Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. , 2005, Brain : a journal of neurology.

[57]  P. Maher.  The effects of stress and aging on glutathione metabolism , 2005, Ageing Research Reviews.

[58]  Christine D. Dijkstra,et al.  Flavonoids Influence Monocytic GTPase Activity and Are Protective in Experimental Allergic Encephalitis , 2004, The Journal of experimental medicine.

[59]  Hideyo Sato,et al.  Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. , 2004, Biochemical and biophysical research communications.

[60]  S. LeVine,et al.  Immunohistochemical localization of phosphorylated protein kinase R and phosphorylated eukaryotic initiation factor‐2α in the central nervous system of SJL mice with experimental allergic encephalomyelitis , 2004, Journal of neuroscience research.

[61]  E. Melamed,et al.  A low molecular weight copper chelator crosses the blood–brain barrier and attenuates experimental autoimmune encephalomyelitis , 2004, Journal of neurochemistry.

[62]  J. Rose,et al.  Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage , 2004, Journal of Neuroimmunology.

[63]  Jette L. Frederiksen,et al.  Nitric oxide synthase expression and enzymatic activity in multiple sclerosis , 2004, Acta neurologica Scandinavica.

[64]  Daniel Offen,et al.  The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy , 2004, Journal of Neurology.

[65]  D. Pitt,et al.  Glutamate uptake by oligodendrocytes , 2003, Neurology.

[66]  J. Geurts,et al.  Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. , 2003, Brain : a journal of neurology.

[67]  V. Gallai†,et al.  Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. , 2003, Archives of neurology.

[68]  J. Hidalgo,et al.  Retracted: Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis , 2003, Journal of neuroscience research.

[69]  Zheng-Xiong Xi,et al.  The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate , 2002, The Journal of Neuroscience.

[70]  Masahiko Watanabe,et al.  Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[71]  G. Filomeni,et al.  Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[72]  D. Dormont,et al.  Role of glutamate transporters in the regulation of glutathione levels in human macrophages. , 2001, American journal of physiology. Cell physiology.

[73]  N. Bruchovsky,et al.  Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc− cystine transporter: a new action for an old drug , 2001, Leukemia.

[74]  D. Pitt,et al.  Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage , 2001, Annals of neurology.

[75]  G. Mann,et al.  Effect of Oxygen on Induction of the Cystine Transporter by Bacterial Lipopolysaccharide in Mouse Peritoneal Macrophages* , 2001, The Journal of Biological Chemistry.

[76]  T. Ishii,et al.  Cloning and Expression of a Plasma Membrane Cystine/Glutamate Exchange Transporter Composed of Two Distinct Proteins* , 1999, The Journal of Biological Chemistry.

[77]  H. Gendelman,et al.  The cellular immunology of multiple sclerosis , 1999, Journal of leukocyte biology.

[78]  M. Morganti-Kossmann,et al.  Neurotransmitters in cerebrospinal fluid reflect pathological activity , 1997, European journal of clinical investigation.

[79]  C. Nathan,et al.  Perspectives Series : Nitric Oxide and Nitric Oxide Synthases Inducible Nitric Oxide Synthase : What Difference Does It Make ? , 2013 .

[80]  T. Owens,et al.  Glutamate metabolism is down‐regulated in astrocytes during experimental allergic encephalomyelitis , 1997, Glia.

[81]  J. Merrill,et al.  The role of nitric oxide in multiple sclerosis , 1997, Journal of Molecular Medicine.

[82]  B. Cronstein,et al.  The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. , 1996, Journal of immunology.

[83]  S. Bannai,et al.  Induction of cystine transport activity in mouse peritoneal macrophages by bacterial lipopolysaccharide. , 1995, The Biochemical journal.

[84]  D. Piani,et al.  Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. , 1994, Journal of immunology.

[85]  W. Dröge,et al.  Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones. , 1991, European journal of biochemistry.

[86]  W. Dröge,et al.  Modulation of lymphocyte functions and immune responses by cysteine and cysteine derivatives. , 1991, The American journal of medicine.

[87]  S. Bannai.  Exchange of cystine and glutamate across plasma membrane of human fibroblasts. , 1986, The Journal of biological chemistry.

[88]  Roland Martin,et al.  The good and the bad of neuroinflammation in multiple sclerosis. , 2014, Handbook of clinical neurology.

[89]  George Perry,et al.  Oxidative stress and neurotoxicity. , 2008, Chemical research in toxicology.

[90]  A. Hatzimanolis,et al.  Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. , 2008, Journal of neuroimmunology.

[91]  L. Ignarro.  Nitric oxide : biology and pathobiology , 2000 .

[92]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.

[93]  L. Turski,et al.  Autoimmune encephalomyelitis ameliorated by AMPA antagonists , 2000, Nature Medicine.

[94]  U. Förstermann,et al.  Regulation of the Expression of Nitric Oxide Synthase Isoforms , 2000 .

[95]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.